Viking Therapeutics Stock: Key Milestone Accelerates Timeline
03.12.2025 - 07:54:04Viking Therapeutics US92686J1060
Viking Therapeutics, a clinical-stage biopharmaceutical company, captured significant investor interest this week following its presentation at the Piper Sandler Healthcare Conference. The firm announced the early completion of patient enrollment for its pivotal Phase 3 trial, VANQUISH-1, a major step forward for its obesity treatment candidate, VK2735.
Trading closed on Tuesday at approximately $33.88 per share, with the equity currently consolidating after a period of notable volatility. The muted market reaction to the positive development underscores a prevailing sense of caution within the broader biotechnology sector.
The core announcement centered on the VANQUISH-1 study, which has enrolled its target of 4,650 participants. Recruitment concluded ahead of schedule in late November, a move Read more...
